Journal
CARBOHYDRATE POLYMERS
Volume 291, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2022.119619
Keywords
Chitooligosaccharides; Drug delivery system; AZD9291; Cyclosporin A; Nanoparticles
Categories
Funding
- National Key R&D Program of China [2019YFD0901800]
- Open Project Funding of the State Key Labo-ratory of Bioreactor Engineering, ECUST [ZDXM2019]
- Fundamental Research Funds for the Central Universities [B18022]
- 111 Project
Ask authors/readers for more resources
A chitooligosaccharide-based nanoparticle with enhanced delivery efficiency and endocytosis was constructed in this study, which improved the therapeutic effect of AZD9291 and overcame drug resistance. The surface charge of the nanoparticles changed in the weakly acidic tumor microenvironment and released drugs in the cytoplasm.
AZD9291 can prolong the survival of patients with non-small cell lung cancer. Unfortunately, resistance to AZD9291 is inevitable and hinders effectiveness. Studies showed the combination of Cyclosporin A (CsA) and AZD9291 could increase the efficacy of AZD9291, but the delivery efficiency of free drugs was limited. A chitooligosaccharide (COS) -based nanoparticle with enhanced delivery efficiency and endocytosis was constructed in this study. The results showed that this pH/redox cascade responsive nanoparticles improved therapeutic effect. The system is small and the surface charge changed from negative to positive according to the weakly acidic tumor microenvironment. After endocytosis, the nanoparticles decomposed and released AZD9291 and CsA in redox-rich cytoplasm. Experiments in vitro and in vivo proved that the nanoparticles overcame the biological barrier and significantly enhanced the anti-tumor effect of AZD9291. The novel multifunctional nanoparticle provides a way to overcome the drug resistance and the possibility of clinical application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available